Alpelisib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg, 150 mg, 200 mg
Reference Brands: Piqray (USA/EU)
Category:
Oncology Cancer Care
Product Description:
Alpelisib, also known by its brand name Piqray, is a targeted kinase inhibitor used in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is indicated for use in postmenopausal women and men whose tumors carry a mutation in the PIK3CA gene and whose disease has progressed during or after prior hormone therapy.
Alpelisib works by selectively inhibiting the phosphatidylinositol-3-kinase (PI3K) alpha pathway, which plays a key role in cancer cell growth, survival, and metabolism. By blocking this pathway, alpelisib helps slow tumor progression and may induce cancer cell death. Its targeted mechanism allows for a more personalized treatment approach in patients with genetically driven breast cancer.
In addition to its approved use in breast cancer, alpelisib is being actively studied for its potential role in treating other types of cancer associated with PI3K pathway alterations. Available as an oral tablet, Piqray represents an important advancement in precision oncology, offering an effective treatment option for patients with limited response to standard hormone therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing